Hospital Quironsalud Sagrado Corazon

Sevilla 48 trials 12 recruiting

48 Registered trials

12 Currently recruiting

Organisation

Hospital Quironsalud Sagrado Corazon

Location

Sevilla, Spain

Identifier

ORG-100042766

Address

Calle De Rafael Salgado 3, 41013, Spain

Departments

-
#40400:Reumatología
7507 Rheumatology
ES10015: Reumatología
ESP019: Oncología
Medical Oncology
Obstetricia
Oncologia medica
Oncology
Oncology Service
Reumatología
Reumatology
Rheumatologist
Rheumatology
Servicio de Oncología
Servicio de Reumatología

Clinical trials at this site (48)

Search interface

A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance… Ended

2023-504996-26-00 Metastatic Castration Resistant Prostate Cancer (mCRPC) 5 2022-07-21
Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One… Ended

2023-504715-33-00 Psoriatic Arthritis 5 2021-09-27
A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended

2023-506368-14-00 Systemic lupus erythematosus (SLE) 5 2021-09-07
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended

2023-504734-21-00 Psoriatic arthritis (PsA) 5 2021-08-30
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended

2023-504716-15-00 Psoriatic Arthritis 6 2021-08-06
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2… Ended

2023-505042-25-00 Locally advanced (inoperable) or metastatic HR+/HER2 br 5 2020-05-05
Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive,… Ended

2024-516847-23-00 ER-positive and HER2-negative metastatic or locally adv 4 2019-08-27
A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended

2023-505223-31-00 Localized ER+ breast cancer 4 2019-06-14
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 To determine whether the addition of palbociclib to adj 5 2015-10-27
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended

2023-507680-19-00 Sjögren’s Syndrome 4 2024-11-28
A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi… Ended

2022-501421-20-00 Gout with hyperuricemia 5 2024-04-09
A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HE… Ended

2023-503251-10-00 Metastatic Breast Cancer or Advanced Non-Small Cell Lun 4 2023-10-10
Phase 3 Study Comparing Zimberelimab with Domvanalimab to Pembrolizumab in Advanced Non-Small Cell Lung Cancer Ended

2022-503071-28-00 Squamous Non-small cell Lung Cancer 5 2023-08-31
The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE) Ended

2024-510872-18-00 Systemic lupus erythematosus (SLE) and cutaneous lupus 4 2022-05-09
Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer Ended

2023-508828-35-01 Patients with advanced hormone receptor-positive/HER2- 5 2022-03-28
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Su… Ended

2024-512142-42-00 Psoriatic Arthritis 5 2021-10-05
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended

2023-509591-42-00 HR-positive/HER2-negative breast cancer 4 2021-05-04
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien… Ended

2023-507415-35-00 Psoriatic Arthritis 5 2021-01-15
Clinical Trial to evaluate the efficacy of immunotherapy in a subset of Hormonal Receptor-positive/HER2-negative advanced breast cancer pati… Ended

2023-508546-17-00 Pre and post-menopausal women with locally advanced or 4 2020-07-01
A Study to Assess Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small … Ended

2023-508083-30-00 Non-small cell lung cancer (NSCLC) 4 2018-07-19
Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg… Ended

2024-516132-10-00 Metastatic breast cancer 4 2016-02-05